---

If you enjoy this content, please share it with a colleague

News | Heart Valve Technology | December 24, 2025

Edwards Lifesciences’ SAPIEN M3 mitral valve replacement system has received U.S. Food and Drug Administration approval for the treatment of mitral regurgitation.

Related Content

Jan. 12, 2026 — HeartLung Corp. has announced U.S. Food and Drug Administration (FDA) clearance of AI-CVD, its AI ...

January 12, 2026

Jan. 6, 2026 — W. L. Gore & Associates’ medical business (Gore) has announced the FDA approval of the Gore Viabahn ...

January 06, 2026

Dec. 22, 2025 — Abbott recently announced the U.S. Food and Drug Administration (FDA) has approved the company’s Volt ...

January 05, 2026

Dec. 18, 2025 — Huxley Medical has announced the SANSA home sleep apnea test has received regulatory clearance from the ...

December 19, 2025

Dec. 18, 2025 — Abbott has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its Amplatzer ...

December 18, 2025

Dec. 15, 2025 — HeartSciences Inc., a healthcare information technology company advancing the use of ECG/EKGs through ...

December 16, 2025

Nov. 25, 2025 — Remington Medical has received U.S. Food and Drug Administration (FDA) 510(k) clearance and announced ...

December 09, 2025

Dec. 3, 2025 — Atraverse Medical, a medical device company developing next-generation left-heart access technology, has ...

December 05, 2025

Dec.1, 2025 – MannKind Corp. has announced that the U.S. Food and Drug Administration (FDA) has accepted the sNDA ...

December 01, 2025

Nov. 18, 2025 — RapidAI announced U.S. Food and Drug Administration (FDA) clearance of Aortic Management, part of the ...

November 18, 2025